Drug intelligence / Profile preview

KNA-145

Development stage: Preclinical
Lead developer: Kinea Bio
Modality: Gene Therapies

Overview

KNA-145 is a gene therapy drug candidate developed by Kinea Bio. It is in preclinical development for the treatment of congenital muscular dystrophy, a group of inherited muscle disorders characterized by muscle weakness and degeneration present at birth. The specific mechanism of action, molecular target, and delivery vector for KNA-145 have not been publicly disclosed as of June 2025. The therapy represents an investigational approach aimed at addressing the underlying genetic causes of congenital muscular dystrophy[1][2][5].

Beyond the preview

Go deeper on KNA-145.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KNA-145.

Explore the full profile